Expenditures under the more expensive BRCA1/2 non-panel CPT code 81162 grew consistently until peaking at $118 million in 2019, costing over 10 times more than the amount paid that year for the 81432 breast cancer panel code. The gene discussed is BRCA1; the disease is breast cancer.